No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
NANOBIOTIX to Introduce Vision for Transforming Drug Design and Development With Next Nanotherapeutic Platform on 19 December 2024
Nanobiotix Executive Acquires Significant Share Volume, Signaling Confidence in Future Growth
Nanobiotix (NBTX) Gets a Buy From Leerink Partners
Nanobiotix ADRs Jump on Completed Pancreatic Cancer Treatment Study
Why C3.ai Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
NANOBIOTIX Announces Completion of Phase 1 Study of NBTXR3 (JNJ-1900) in Pancreatic Cancer
No Data